Description
ARA 290 16mg vial
Important Notices:
This product is sold for scientific research purposes only.
Product is provided as a lyophilized (freeze-dried) powder in a sealed, sterile vial.
The quantity on the label refers to the total amount of product inside each vial.
Additional lab supplies are required for conducting research such as bacteriostatic water for reconstitution, syringes & needles to draw from the vials, and alcohol prep pads for sanitizing vial stoppers prior to needle insertion.
Vial appearance, label, seal and cap colors may vary from product photos.
ARA-290, also known as Cibinetide, is a synthetic peptide derived from the helix beta domain of erythropoietin (EPO). Unlike EPO, which primarily stimulates red blood cell production, ARA-290 targets the innate repair receptor (IRR) to provide neuroprotective and pain-relieving effects without affecting erythropoiesis. This makes ARA-290 a promising therapeutic agent for managing neuropathic pain, reducing chronic inflammation, and promoting tissue repair. ARA-290 is currently in Phase II and III clinical trials for conditions such as diabetic neuropathy, sarcoidosis, and more.
- pain management: Effectiveness: ARA-290 has shown significant efficacy in reducing neuropathic pain, particularly in conditions like small fiber neuropathy, often seen in diabetes and sarcoidosis. It inhibits TRPV1 channel activity, which is responsible for the perception of burning pain, leading to reduced pain sensitivity. Clinical Evidence: ARA-290 can lead to meaningful reductions in pain within 30 days, with effects lasting up to six months. In clinical trials, patients with moderate to severe pain reported a significant decrease in pain intensity.
- anti-inflammatory: Mechanism: ARA-290 reduces chronic inflammation by inhibiting the secretion of pro-inflammatory cytokines such as IL-6, IL-12, and TNF-alpha. This effect is crucial for managing autoimmune conditions and reducing systemic inflammation Clinical Evidence: ARA-290 significantly reduces inflammatory responses, as seen in models of islet transplants and other inflammatory conditions.
- nerve repair and regeneration: Functionality: ARA-290 promotes nerve fiber regeneration and enhances functional recovery in conditions associated with nerve damage, such as diabetic neuropathy and sarcoidosis-induced neuropathy. Clinical Evidence: In a Phase 2b trial, ARA-290 significantly increased corneal nerve fiber abundance, leading to improved functional activity and reduced pain.
- Tissue Protection and Wound Healing: Healing Acceleration: ARA-290 accelerates wound healing, particularly in diabetic models, by promoting blood vessel growth and reducing oxidative stress. This peptide enhances the survival of transplanted islet cells, crucial for diabetes management.
- Other Potential Benefits: Cardiovascular Health: ARA-290 has shown potential in enhancing blood vessel health, particularly in conditions like retinal ischemia, which can lead to blindness. The peptide helps protect and regenerate blood vessels by promoting the proliferation and longevity of endothelial colony-forming cells. Immune Modulation: ARA-290 can modulate immune responses, making it a potential treatment for conditions like systemic lupus erythematosus (SLE) and inflammatory bowel diseases like colitis. Antidepressant Effects: There is emerging evidence that ARA-290 might exert antidepressant effects, although this is still under investigation.
